I-Pomalidomide, eyayisaziwa ngaphambili njenge-CC-4047 okanye i-actimid, yi-molecule enamandla ye-immunomodulatory ebonisa umsebenzi we-antineoplastic kunyango lwe-hematological malignancies, ngakumbi ukubuyisela kwakhona kunye ne-refractory myeloma emininzi (MM). Njengoko i-derivative ye-thalidomide, i-pomalidomide inesakhiwo esifanayo sekhemikhali njenge-thalidomide ngaphandle kokongezwa kwamaqela amabini e-oxo kwindandatho ye-phthaloyl kunye neqela le-amino kwindawo yesine. Ngokubanzi, njengemolekyuli ye-immunomodulatory, i-pomalidomide ibonisa umsebenzi we-antitumor ngokusebenzisa indlela yokuthintela i-tumor microenvironment ngokumodareyitha i-cytokines exhasa ithumba (TNF-α, IL-6, IL-8 kunye neVEGF), ilawula ngokuthe ngqo imisebenzi ephambili ye-tumor. iiseli, kunye nenkxaso ebandakanyekayo evela kwiiseli ezingamajoni omzimba.

I-pomalidomide isetyenziselwa ukunyanga i-myeloma eninzi (umhlaza obangelwa sisifo segazi esiqhubekayo). I<em>pomalidomide idla ngokunikezelwa emva kokuba amanye amayeza amabini ezamekile ngaphandle kwempumelelo.

IPomalidomide ikwasetyenziselwa ukunyanga iKaposi sarcoma enxulumene noGawulayo xa amanye amayeza engasebenzi okanye eyekile ukusebenza. i-pomalidomide ingasetyenziselwa ukunyanga i-Kaposi Sarcoma kubantu abadalaHIV-negative.

I-Pomalidomide ifumaneka kuphela kwikhemesti eqinisekisiweyo phantsi kwenkqubo ekhethekileyo. Kufuneka ubhalise kwinkqubo kwaye uvume ukusebenzisaukulawula inzalaamanyathelo njengoko kufuneka.

IPomalidomide ingasetyenziselwa iinjongo ezingadweliswanga kwesi sikhokelo samayeza.

IPomalidomide inokubangela iziphene ezimandundu, ezibeka ubomi esichengeni okanye ukufa komntwana ukuba umama okanye utata usebenzisa ipomalidomide ngexesha lokukhawulwa okanye ngexesha lokukhulelwa. Kwanethamo elinye lepomalidomide linokubangela iziphene ezinkulu kwiingalo nemilenze yosana, amathambo, iindlebe, amehlo, ubuso nentliziyo. Ungaze usebenzise i-pomalidomide ukuba ukhulelwe. Tshela ugqirha wakho ngokukhawuleza ukuba ixesha lakho liphelile ngelixa uthatha i-pomalidomide.